Cargando…

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of BCR-ABL1 mutations, activation of additional pro-oncogenic pathways, and stem cell resistance. Drug combinations covering a broad range of targets may overcome resistance. CDDO-Me (bardoxolone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gleixner, Karoline V., Schneeweiss, Mathias, Eisenwort, Gregor, Berger, Daniela, Herrmann, Harald, Blatt, Katharina, Greiner, Georg, Byrgazov, Konstantin, Hoermann, Gregor, Konopleva, Marina, Waliul, Islam, Cumaraswamy, Abbarna A., Gunning, Patrick T., Maeda, Hiroshi, Moriggl, Richard, Deininger, Michael, Lion, Thomas, Andreeff, Michael, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685220/ https://www.ncbi.nlm.nih.gov/pubmed/28596283 http://dx.doi.org/10.3324/haematol.2016.163436

Ejemplares similares

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Pharmacologic inhibition of STAT5 in acute myeloid leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2018)

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
por: Wingelhofer, Bettina, et al.
Publicado: (2018)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Targeting STAT3 and STAT5 in Cancer
por: de Araujo, Elvin D., et al.
Publicado: (2020)

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
por: Maurer, Barbara, et al.
Publicado: (2020)

Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein
por: Cumaraswamy, Abbarna A., et al.
Publicado: (2014)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
por: Byrgazov, Konstantin, et al.
Publicado: (2016)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Direct Targeting Options for STAT3 and STAT5 in Cancer
por: Orlova, Anna, et al.
Publicado: (2019)

STAT5 is Expressed in CD34(+)/CD38(−) Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
por: Hadzijusufovic, Emir, et al.
Publicado: (2020)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
por: Hoermann, Gregor, et al.
Publicado: (2015)

Structural Implications of STAT3 and STAT5 SH2 Domain Mutations
por: de Araujo, Elvin D., et al.
Publicado: (2019)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

JAK‐STAT core cancer pathway: An integrative cancer interactome analysis
por: Erdogan, Fettah, et al.
Publicado: (2022)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
por: Hoermann, Gregor, et al.
Publicado: (2020)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
por: Gordziel, C, et al.
Publicado: (2013)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies
por: Freund, P, et al.
Publicado: (2017)

Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
por: Valent, Peter, et al.
Publicado: (2021)

Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal
por: Willmann, Michael, et al.
Publicado: (2021)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Acetylation and sumoylation control STAT5 activation antagonistically
por: Krämer, Oliver H., et al.
Publicado: (2012)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
por: Yamatani, Kotoko, et al.
Publicado: (2022)

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
por: Graf, Irene, et al.
Publicado: (2023)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling
por: Phi, Ji Hoon, et al.
Publicado: (2015)

SBNO2 is a critical mediator of STAT3-driven hematological malignancies
por: Brandstoetter, Tania, et al.
Publicado: (2023)

The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth
por: Nivarthi, Harini, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nohs1g2f9tjr12k37rels66buh